Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.30 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.30 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1688691 | 1.00 | MAPK14 (0.32) | MAPK14MTORRICTORMAPKAP1MLST8 | |
| SCHEMBL1688676 | 0.89 | MAPK14 (0.31) | MAPK14MTORRICTORMAPKAP1MLST8 | |
| SCHEMBL2690354 | 0.89 | MAPK14 (0.31) | MAPK14MTORRICTORMAPKAP1MLST8 | |
| SCHEMBL2691221 | 0.89 | — | — | |
| SCHEMBL2690431 | 0.89 | — | — | |
| SCHEMBL2049048 | 0.86 | PLK1 (0.37) | MAPK14MTORRICTORMAPKAP1MLST8 | |
| SCHEMBL2336446 | 0.86 | PLK1 (0.37) | MAPK14MTORRICTORMAPKAP1MLST8 | |
| SCHEMBL2049045 | 0.86 | PLK1 (0.37) | MAPK14MTORRICTORMAPKAP1MLST8 | |
| SCHEMBL2691733 | 0.85 | TRPM8 (0.33) | MTORRICTORMAPKAP1MLST8 | |
| SCHEMBL2689184 | 0.85 | TRPM8 (0.33) | MTORRICTORMAPKAP1MLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | PLK1, POLR2E, POLR2H | MAPK14 883/4885MTOR 594/4885RICTOR 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.